Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer

BACKGROUND: Liquid biopsy has the potential to monitor biological effects of treatment. KRAS represents the most commonly mutated oncogene in Caucasian non-small-cell lung cancer (NSCLC). The aim of this study was to explore association of dynamic plasma KRAS genotyping with outcome in advanced NSCL...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Zulato, Elisabetta, Attili, Ilaria, Pavan, Alberto, Nardo, Giorgia, Del Bianco, Paola, Boscolo Bragadin, Andrea, Verza, Martina, Pasqualini, Lorenza, Pasello, Giulia, Fassan, Matteo, Calabrese, Fiorella, Guarneri, Valentina, Amadori, Alberto, Conte, PierFranco, Indraccolo, Stefano, Bonanno, Laura
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7341732/
https://ncbi.nlm.nih.gov/pubmed/32376889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0833-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky